z-logo
Premium
A working model for hypothermic neuroprotection
Author(s) -
Wassink Guido,
Davidson Joanne O.,
Lear Christopher A.,
Juul Sandra E.,
Northington Frances,
Bennet Laura,
Gunn Alistair J.
Publication year - 2018
Publication title -
the journal of physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.802
H-Index - 240
eISSN - 1469-7793
pISSN - 0022-3751
DOI - 10.1113/jp274928
Subject(s) - neuroprotection , hypothermia , neuroscience , encephalopathy , medicine , ischemia , hypoxia (environmental) , programmed cell death , erythropoietin , apoptosis , pharmacology , bioinformatics , anesthesia , biology , chemistry , biochemistry , organic chemistry , oxygen
Therapeutic hypothermia significantly improves survival without disability in near‐term and full‐term newborns with moderate to severe hypoxic–ischaemic encephalopathy. However, hypothermic neuroprotection is incomplete. The challenge now is to find ways to further improve outcomes. One major limitation to progress is that the specific mechanisms of hypothermia are only partly understood. Evidence supports the concept that therapeutic cooling suppresses multiple extracellular death signals, including intracellular pathways of apoptotic and necrotic cell death and inappropriate microglial activation. Thus, the optimal depth of induced hypothermia is that which effectively suppresses the cell death pathways after hypoxia–ischaemia, but without inhibiting recovery of the cellular environment. Thus mild hypothermia needs to be continued until the cell environment has recovered until it can actively support cell survival. This review highlights that key survival cues likely include the inter‐related restoration of neuronal activity and growth factor release. This working model suggests that interventions that target overlapping mechanisms, such as anticonvulsants, are unlikely to materially augment hypothermic neuroprotection. We suggest that further improvements are most likely to be achieved with late interventions that maximise restoration of the normal cell environment after therapeutic hypothermia, such as recombinant human erythropoietin or stem cell therapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here